NXGL News & Events

NexGel (NXGL) announced the signing of a definitive agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity (CELU), a regenerative and cellular medicine company. The transaction represents the most significant milestone in the Company's history and is expected to approximately triple NEXGEL's revenue base and expected to make the Company profitable immediately upon closing.

NEXGEL announced the financing of $1.797M relating to a potential acquisition targeted for the first quarter of 2026. The potential acquisition is subject to the completion of due diligence by both NEXGEL and the investor. The funds will be returned to the investor should the transaction not be consummated.

NEXGEL announced that NexGelRx, the Company's previously announced spin-off of select drug delivery application assets, has received strategic investments from Eric Gruntfest and Ariel Imas of Diesis Holdings. In connection with the investment, NexGelRx has appointed Mr. Gruntfest to serve as a board observer and advisor, bringing deep experience in reimbursement strategy, patient access, and healthcare-commercialization leadership. Gruntfest is a seasoned healthcare executive with over 20 years of experience spanning reimbursement management, payer solutions, and patient support programs. He currently serves as Managing Partner for Diesis Holdings and as CEO of RMBB Health.

NEXGEL announced the spin-off of select drug delivery application assets into NexGelRx, an entity which will focus exclusively on developing and commercializing prescription drug delivery solutions utilizing NEXGEL's proprietary hydrogel technology. At the time of the spin-off, NexGelRx also closed an initial funding from outside investors. Under the terms of the license agreement, NEXGEL will receive a 5% royalty, in perpetuity, for the global rights to its technology for Rx drug delivery by NexGelRx. NEXGEL will also retain a 19.99% equity stake in NexGelRx, which is non-dilutive for up to $8M of capital investment into NexGelRx. Nexgel will also be the exclusive manufacturer of hydrogel for NexGelRx.